ZeppetellaG, O'DohertyCA, CollinsS. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage, 2000; 20:87–92.
2.
CaraceniA, MartiniC, ZeccaE. Breakthrough pain characteristics and syndromes in patients with cancer pain: An international survey. Palliat Med, 2004; 18:177–183.
3.
KressHG, OronskaA, KaczmarekZ, KaasaS, ColbergT, NolteT. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: A phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther, 2009; 31:1177–1191.
4.
MercadanteS, RadbruchL, DaviesA, PoulainP, SitteT, PerkinsP, ColbergT, CambaMA. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: An open-label, randomised, crossover trial. Curr Med Res Opin, 2009; 25:2805–2815.
5.
Veldhorst-JanssenNM, FiddelersAA, van der KuyPH, NeefC, MarcusMA. A review of the clinical pharmacokinetics of opioids, benzodiazepines, and antimigraine drugs delivered intranasally. Clin Ther, 2009; 31:2954–2987.
6.
AtkinsonMJ, SinhaA, HassSL, ColmanSS, KumarRN, BrodM, RowlandCR. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes, 2004; 2:12.
7.
FarrarJT, PolomanoRC, BerlinJA, StromBL. A comparison of change in the 0-10 numeric rating scale to a pain relief scale and global medication performance scale in a short-term clinical trial of breakthrough pain intensity. Anesthesiology, 2010; 112:1464–1472.
